20 February 2024
New winter school on ‘future chips’ in Eindhoven brings together world-leading parties on semiconductors and photonics
- International talent
- International student
- Micro- and nano electronics
- Blogs work
- Digital technologies
Milestone in the development of contraception of the future.
Years ago, Peter van de Graaf laid the foundation for start-up Choice for Women. It was born from a deep desire to make the world a bit more beautiful. The Industrial Designer’s dream is that ultimately children will only be conceived when they are really wanted. With a team of about 40 highly motivated engineers, professors, gynecologists and other professionals, Peter is working on the contraception of the future: a valve in the fallopian tube based on microtechnology that opens when needed. Choice has reached an important milestone: the first animal experiments have started.
“Developing Choice for Women has taken a long time,” says Peter. “I thought of the idea years ago when I was feeling restless about where our planet is going to. I once read about how a solution was developed for children with hydrocephalus. The idea to remove the cerebrospinal fluid with a drain was invented by a plumber with a child with hydrocephalus. He was not able to save his own child, but now children with hydrocephalus can lead a normal life. To me that was so inspiring that it led to the idea of finding a solution that helps in only conceiving children when they are really wanted. Then I thought of using micro-technology to develop blockages for women’s fallopian tubes that they can open and close form a distance so that they can control the moment that they are ready for conceiving a child.
"What is tricky when it comes to these kinds of ideas is that you can't immediately quit your job and fully devote yourself to working on it. By coincidence I ended up at Eindhoven University of Technology as a Coach Industrial Design. That enabled me to build a very relevant network. Later I started working as a teacher at Windesheim University of Applied Sciences for three days a week so that I could spend the rest of my time on developing my company. My brother is a businessman and also joined the company. We applied for a patent at the end of 2015 and at that time we started looking for investments.”
“That turned out to be quite difficult. A number of our requests were denied, and the media offensive we launched, did not lead to investments either. I am an Industrial Engineer and suddenly I had to finance a start-up. That is not my field of expertise. Fortunately, I encountered Ruud van Iwaarden and Marielle Sleumer of Brainport Development through the TU/e Innovation Lab. Ruud referred me to the Brabant Startup Fund and connected me with Rabobank. That helped me to acquire early stage financing. Brainport's guidance has brought me a lot further. ”
“We have therefore chosen to make a relatively simple product at first, and to gradually add functionalities in later phases. As a result, we can enter the market earlier, without losing sight of our goal. The first version is now in the animal testing phase, we are testing it on rabbits. Ultimately we want to develop the so-called Choice Two that can be switched wirelessly. We are currently discussing this with Imec. ”
“Our core team is very small. It consists of myself, an engineer and someone who does market research. Besides that, we can rely on a very extensive pool of experts and labs that we use in a flexible manner. If we had a lab ourselves, we would have needed a lot more funding, but fortunately there are a lot of highly qualitative and innovative labs in the region that we can use, such as the EPC lab of the TU/e. In total, we work together with about 30 to 40 experts, including two professors of gynecology. Lifetec has also conducted research for us, for example. Those contacts all come from my network at TU / e. We only work with people who want to go for this and you notice that, people are extremely motivated to contribute to this. ”
“To investors, this is not a fast exit product. We will start clinical tests in eighteen months to two years. So in total it will take about four to five years before a first product is on the market. In addition, besides finding investors, it is essential to be able to rely on a very good team. People who can think in an innovative way. It is also important not to have a technology push, but a market-pull product: women's organizations that endorse our product for example. Female engineers who want to contribute to our product are also very welcome. In both technology and among investors, you will mainly find men in the Netherlands. Given the nature of this product, a female engineer would be very welcome in our team. ”